Partners Group Holding AG is nearing a deal to acquire European generic drugmaker Pharmathen SA from BC Partners for around $1.9bn, according to people familiar with the matter.
The buyout firms could announce an agreement in the coming days, the people said, asking not to be identified discussing confidential information. Partners Group preempted other private equity and strategic bidders to win the planned auction of the drugmaker, they said.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
Founded in 1969 in Athens, Pharmathen develops and manufactures generic drugs that can be administered via tablets, drops and injection. Last year, the company had more than 30 products being lined up for launch, with a focus on the lucrative U.S. market, according to a company video. BC Partners acquired Pharmathen from its founding family for 475 million euros in 2015.
BC Partners is selling the business for around 20 times earnings, double the multiple it paid in 2015, according to people familiar with the matter. BC Partners invested in the business during a year of heightened financial market volatility for Greece. It’s been one of the most lucrative investments from BC’s 9th buyout fund.
Source: BNN Bloomberg
Can’t stop reading? Read more
Exclusive Interview: Andrei Gemeneanu on building Romania’s private equity future
Exclusive Interview: Andrei Gemeneanu on building Romania's private equity future Andrei...
Shore Capital’s Justin Ishbia agrees $1.8bn path to control of MLB’s Chicago White Sox
Shore Capital’s Justin Ishbia agrees $1.8bn path to control of MLB’s Chicago White Sox Justin...
EQT to acquire controlling stake in Waga Energy in €534m clean energy push
EQT to acquire controlling stake in Waga Energy in €534m clean energy push EQT is set to acquire a...